Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.34 |
| ▸ | HTT | P42858 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373864 | 0.83 | MAPK14 (0.32) | KDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL14287102 | 0.77 | MAPT (0.37) | KDM4EALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL14287126 | 0.77 | BTK (0.34) | CYP1A2CYP2C19SMN1; SMN2MAPTCYP2C9 | |
| SCHEMBL14287078 | 0.77 | MAPK14 (0.33) | KDM4EALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL14287081 | 0.77 | ALDH1A1 (0.38) | ALDH1A1HPGDSMN1; SMN2MAPTCYP2D6 | |
| SCHEMBL4367402 | 0.76 | MAPK14 (0.35) | LMNAMEN1KMT2ATDP2TP53 | |
| SCHEMBL6610168 | 0.76 | CYP11B1 (0.39) | ALDH1A1HTTCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL14287101 | 0.76 | MAPT (0.33) | KDM4EALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL14287093 | 0.75 | CHEK1 (0.34) | KDM4EALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL3839886 | 0.75 | NPC1 (0.36) | HPGDKMT2ACAMK2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269230-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-10-30 | — | — | US | claimed |
| US-20060079529-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2006-04-13 | — | — | US | claimed |
| US-20040142936-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | NEUROSEARCH A/S | 2004-07-22 | — | — | US | claimed |
| US-20020058663-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | AROS PHARMA APS (DK) | 2002-05-16 | — | — | US | claimed |
| US-20080269230-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-10-30 | — | — | US | disclosed |
| US-7288653-B2 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-10-30 | — | — | US | disclosed |
| US-20060079529-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | PAINCEPTOR PHARMA CORPORATION (CA) | 2006-04-13 | — | — | US | disclosed |
| EP-0869958-B1 | NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH AS (DK) | 2004-12-29 | — | — | EP | disclosed |
| EP-1066037-B1 | USE OF INDOLE-2,3-DIONE-3-OXIME DERIVATIVES AS AMPA ANTAGONISTS | NEUROSEARCH AS (DK) | 2004-12-29 | — | — | EP | disclosed |
| US-20040142936-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | NEUROSEARCH A/S | 2004-07-22 | — | — | US | disclosed |
| US-6727260-B2 | USING COMPOUNDS CAPABLE OF INHIBITING THE ACTIVITY OF A PROTON-GATED CATION CHANNEL IN THERAPY OR ALEVIATION OF DISEASES OR DISORDERS ASSOCIATED WITH, OR MEDIATED BY A DROP IN EXTRACELLULAR PH | NEUROSEARCH A/S (DK) | 2004-04-27 | — | — | US | disclosed |
| US-6693111-B1 | 1H-PYRROLO(3,2-H)ISOQUINOLINE DERIVATIVES; EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | NEUROSEARCH A/S (DK) | 2004-02-17 | — | — | US | disclosed |
| EP-0869958-A1 | NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| US-5780493-A | TREATING BRAIN DISORDERS | NEUROSEARCH A/S (DK) | 1998-07-14 | — | — | US | disclosed |
| WO-1998014447-A1 | NOVEL INDOLE-2,3-DIONE-3-OXIME DERIVATIVES | NEUROSEARCH A/S (DK) | 1998-04-09 | — | — | WO | disclosed |
| EP-0698025-B1 | AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH | NEUROSEARCH AS (DK) | 1997-12-17 | — | — | EP | disclosed |
| EP-0781284-A1 | INDOLE-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008494-A1 | INDOLE-2,3-DIONE-3-OXIME DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1996-03-21 | — | — | WO | disclosed |
| EP-0698025-A1 | AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH | NEUROSEARCH A/S (DK) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994026747-A1 | AMPA ANTAGONISTS AND A METHOD OF TREATMENT THEREWITH | NEUROSEARCH A/S (DK) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079529-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | KDM4E 3902/4885ALDH1A1 2854/4885HPGD 350/4885 |
| US-20080269230-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | KDM4E 3902/4885ALDH1A1 2854/4885HPGD 350/4885 |
| US-20020058663-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | ASIC1, ASIC3, TRPM4 | KDM4E 4094/4885ALDH1A1 2160/4885HPGD 745/4885 |
| US-20040142936-A1 | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | TRPV1, HVCN1, TRPM2 | KDM4E 3902/4885ALDH1A1 2854/4885HPGD 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.